As part of the European Union 7th Framework for Health, the “Beta-JUDO” project will involve hundreds of juveniles with obesity and type 2 diabetes. Pharmacology-based treatment strategies are limited for this growing patient group and the aim of the project is to identify novel strategies reducing insulin hyper secretion, which has so far not been considered a target for intervention in young obese individuals. The project will also involve beta-cell biology, brown adipocyte imaging, transcript and protein profiling, genetics, epidemiology and bioinformatics. A number of European institutions with expertise in these areas are thus involved. A kick-off for the project was recently held at Uppsala University, where about 30 expert scientists form several European countries attended. The project will continue until 2016 and has a total budget of €8 million.
OpenClinica will be used for data collection and data management across several European countries. The project is led by Professor Peter Bergsten Department of Medical Cell Biology at Uppsala University and two firms, Scandinavian CRO and e-Source Technology EMR, will be responsible for the management of the clinical part of the project.
We are proud to be involved in this prestigious project and to be able to demonstrate the abilities of OpenClinica and its powerful web services, which will facilitate the integration of external data from many sources across Europe.
– Dr. Krister Kristianson
e-Source Technology EMR
The chance to get discounted early bird rates on registration and training for the 2012 OpenClinica Global Conference ends this Friday, February 17th–so register today!
The 2012 OpenClinica Global Conference, April 22-23 in Boston, is a great opportunity to:
- Learn what’s possible with open source EDC and the fastest growing clinical trials software
- Hear case studies and best practices
- Obtain ideas and techniques for how to better use OpenClinica
- Acquire new skills through tutorials and training
- Develop contacts with people who live and breathe OpenClinica
We are excited to have Dr. Tomasz Sablinski, founder and CEO of Transparency Life Sciences deliver this year’s keynote. His presentation titled “Breaking Barriers: Forging a New Model for Clinical Development” describes an innovative new “open source” model for clinical development. Truly innovative stuff!
The deadline for submitting session proposals, posters, and exhibits/demonstrations is also Feb. 17th.
Be sure to visit the OpenClinica Conference website, where you can register, view more information about the event program, and see pictures and videos from last year’s conference.
Could the principles of open source and open innovation transform the future of clinical research? Come hear thought leader and innovator Dr. Tomasz Sablinski deliver the keynote presentation titled “Breaking Barriers: Forging a New Model for Clinical Development” at the 2012 OpenClinica Conference on April 23rd in Boston.
The world has shown that it is possible to harness the power of crowds to deliver incredibly successful innovation and services (think Facebook, Wikipedia, Linux). However, this style of innovation is relatively absent within the domain of clinical research. Sablinski believes the time may be ripe to borrow from the principles of open source and telemedicine in order to create a new, more effective model for clinical development.
Dr. Sablinski’s ideas have profound implications. However, while bold and thought provoking, they are more than academic. He puts his money where his mouth is–Sablinski’s start-up company, Transparency Life Sciences, has set out to increase the efficiency of clinical development leveraging open principles that turn much of the current way of thinking on its head.
Dr. Sablisnki’s assessments of the current state of clinical development are based on over 30 years in the field, as a practicing physician, basic researcher, drug developer, investor, and now, entrepreneur. He has served as a researcher at Harvard Medical School, a Medical Director at Parexel, VP of Clinical Development at Novartis, and Head of Development and Managing Director at private equity firm Celtic Therapeutics.
We look forward to hosting Dr. Sablinski at this year’s OpenClinica Global Conference!
– Ben Baumann
Chair, OpenClinica Conference Committee